Provided by Tiger Fintech (Singapore) Pte. Ltd.

Aclaris Therapeutics

1.44
-0.0100-0.69%
Post-market: 1.460.0191+1.33%16:20 EDT
Volume:401.67K
Turnover:585.57K
Market Cap:155.92M
PE:-1.00
High:1.49
Open:1.46
Low:1.44
Close:1.45
Loading ...

Aclaris Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
27 Feb

Aclaris Therapeutics (ACRS) Reports Q4 Loss, Tops Revenue Estimates

Zacks
·
27 Feb

Aclaris: Q4 Earnings Snapshot

Associated Press Finance
·
27 Feb

Aclaris Therapeutics Q4 2024 GAAP EPS $(1.01) Misses $(0.24) Estimate, Sales $9.21M Beat $2.11M Estimate

Benzinga
·
27 Feb

Aclaris Therapeutics reports Q4 EPS ($1.01), consensus (38c)

TIPRANKS
·
27 Feb

BRIEF-Aclaris Therapeutics Q4 Revenue USD 9.211 Million Vs. IBES Estimate USD 2.11 Million

Reuters
·
27 Feb

Aclaris Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update

GlobeNewswire
·
27 Feb

Aclaris Therapeutics Inc expected to post a loss of 22 cents a share - Earnings Preview

Reuters
·
21 Feb

Aclaris Therapeutics announces publication describing properties of ATI-2138

TIPRANKS
·
12 Feb

New Publication Highlights Unique Properties of ATI-2138, a Potent and Selective Inhibitor of ITK and JAK3

GlobeNewswire
·
12 Feb

Aclaris Therapeutics Announces Formation of New Scientific Advisory Board

THOMSON REUTERS
·
31 Jan

Aclaris Therapeutics Announces Formation of New Scientific Advisory Board

GlobeNewswire
·
31 Jan

Aclaris Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Reuters
·
07 Jan

Aclaris Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
07 Jan

Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire
·
07 Jan